BMS Keeping A Watchful Eye On Tariffs, Pricing And Other Policy Changes

Q1 Beat Driven By Legacy Drugs, Not Growth Portfolio

 
• By Mandy Jackson
  
BMS updated its guidance to reflect Chinese tariffs on US-manufactured products, but is awaiting updated US policy for further tariff updates (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Scrip